<DOC>
	<DOCNO>NCT00943358</DOCNO>
	<brief_summary>The purpose study evaluate antibody response one two dos influenza A/H1N1v vaccine healthy adult .</brief_summary>
	<brief_title>Safety Immunogenicity A/H1N1v Vaccines Healthy Adults</brief_title>
	<detailed_description>An observer-blind , single-centre study 7 group 25-30 male female adult ≥18-50 year age randomly allocate receive two dos cell culture non-adjuvanted MF59-adjuvanted influenza A/California/4/2009 ( H1N1 ) surface antigen vaccine contain 3.75 , 7.5 15µg haemagglutinin intramuscular injection . A second dose vaccine contain quantity antigen first dose administer 21 day later . Three additional group receive two dos MF59-adjuvanted influenza A/California/4/2009 ( H1N1 ) surface antigen vaccine contain 7.5 µg haemagglutinin intramuscular injection day 0 separate 7 14 day . Subjects observe local systemic reaction 30 minute immunisation monitor reaction adverse event 7 day immunisation .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Mentally competent adult , sign informed consent form receive detailed explanation study protocol . 2 . Male female subject 1850 year either healthy stable medical condition . 3 . Able understand comply study procedure complete study diary 4 . Individuals contact throughout study available study visit 5 . Females either use secure contraceptive precaution include : oral contraceptive pill condom/barrier contraception partner vasectomy surgically sterilise , postmenopausal ( define least two year since last menstrual period ) 1 . Any clinically significant concurrent illness unstable medical condition include : malignant tumour , autoimmune illness ( include rheumatoid arthritis ) , acute progressive renal hepatic pathology , chronic obstructive pulmonary disease require oxygen therapy , active neurological disorder . 2 . Individuals history anaphylaxis serious reaction vaccine ; hypersensitivity influenzal viral protein , neomycin polymixin , product contain mercury . 3 . Persons know immunosuppressive disease use systemic immunosuppressive drug drug list section 8 British National Formulary ( BNF ) chloroquine , gold penicillamine drug list section 10.1.3 BNF suppress chronic disease process , receive last 6 month radiotherapy chemotherapy . 4 . Subjects high risk develop illness immune system . 5 . Individuals take immunostimulant therapy interferon 6 . Individuals receive blood product immunoglobulins parenterally preceding three month . 7 . Women pregnant lactating . 8 . Women refuse use reliable contraceptive method throughout study 9 . Known suspected drug abuse . 10 . Individuals receive another vaccine investigational medicinal product precede 2 week . 11 . Unable lead independent life either physically mentally 12 . Regularly drink 40 unit alcohol weekly 13 . Individuals acute respiratory pathology infection require systemic antibiotic antiviral therapy precede 7 day ( chronic antibiotic therapy prevention urinary tract infection acceptable ) . 14 . Individuals temperature &gt; 38oC precede 3 day . 15 . Individuals , opinion investigator , condition might complicate interpretation study result . 16 . Individuals confirm pandemic influenza H1 infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>influenza</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>vaccine</keyword>
</DOC>